---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-164890"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2023-06-12T23:59:59+00:00"
generated_at: "2026-06-14T02:58:05.653983+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NTLA-2002 Phase 1 data: 95% mean HAE attack reduction; 9 of 10 patients attack free

## Summary
- Single 25-75 mg dose of NTLA-2002 (n=10) produced 95% mean reduction in monthly HAE attack rate through median 9-month follow-up.
- All 9 patients achieving >60% plasma kallikrein reduction remain completely attack free since 16-week observation; longest attack-free interval 13.0 months.
- All 6 patients who discontinued long-term HAE prophylaxis after NTLA-2002 have reported no subsequent attacks.
- Safety: no dose-limiting toxicities, no serious adverse events, no Grade 3+ events; most adverse events mild and transient.
- Phase 2 portion of study now dosing; Intellia expects to complete enrollment in H2 2023.

## SEC filing metadata
- accession: 0001193125-23-164890
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2023-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312523164890/0001193125-23-164890-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312523164890/d517852d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-164890
- JSON: https://secwatch.observer/filing/0001193125-23-164890.json
- Plain text: https://secwatch.observer/filing/0001193125-23-164890.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.